PHAR vs. SVRA, AVTE, IRON, PRAX, COGT, YMAB, SLN, SIGA, WVE, and EOLS
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Savara (SVRA), Aerovate Therapeutics (AVTE), Disc Medicine (IRON), Praxis Precision Medicines (PRAX), Cogent Biosciences (COGT), Y-mAbs Therapeutics (YMAB), Silence Therapeutics (SLN), SIGA Technologies (SIGA), Wave Life Sciences (WVE), and Evolus (EOLS). These companies are all part of the "pharmaceutical preparations" industry.
Savara (NASDAQ:SVRA) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment.
In the previous week, Pharming Group had 2 more articles in the media than Savara. MarketBeat recorded 7 mentions for Pharming Group and 5 mentions for Savara. Savara's average media sentiment score of 0.77 beat Pharming Group's score of 0.68 indicating that Pharming Group is being referred to more favorably in the news media.
Savara has a net margin of 0.00% compared to Savara's net margin of -4.13%. Savara's return on equity of -4.53% beat Pharming Group's return on equity.
Savara currently has a consensus target price of $8.20, suggesting a potential upside of 84.27%. Pharming Group has a consensus target price of $37.00, suggesting a potential upside of 285.42%. Given Savara's higher possible upside, analysts clearly believe Pharming Group is more favorable than Savara.
Pharming Group has higher revenue and earnings than Savara. Pharming Group is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.
87.9% of Savara shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 4.6% of Savara shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Savara received 273 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 65.74% of users gave Savara an outperform vote while only 50.00% of users gave Pharming Group an outperform vote.
Savara has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.
Summary
Savara and Pharming Group tied by winning 8 of the 16 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
